SEC Form 4 · accession 0001640455-18-000043
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Gayle Duncan
Director
Period of report
Mar 15, 2018
Accepted (ET)
Mar 19, 2018 · 6:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 15, 2018 | M | 2,000 | $4.21 | A | 2,000 | D | |
| Common Stock | Mar 15, 2018 | S | 2,000 | $28.11 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $4.21 | Mar 15, 2018 | M | 2,000 | D | — | May 9, 2026 | Common Stock | 2,000 | 44,271 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions.
- F2The option shares vest and become exercisable in 16 quarterly installments from May 10, 2016.